Completed PHASE2 INTERVENTIONAL NCT00122538

Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)

HAART Regimen Comprising 3TC + ddI + EFV in Once-daily Administration in HIV-1 Infected Children in Burkina Faso

Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Interventions Didanosine (ddI) Efavirenz (EFV) Lamivudine (3TC)

Updated 5 times since 2017 Last updated: Dec 2, 2011 Started: Feb 28, 2006 Primary completion: Nov 30, 2008 Completion: May 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates AIDS and HIV Infections and is currently completed. French National Agency for Research on AIDS and Viral Hepatitis leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

French National Agency for Research on AIDS and Viral Hepatitis

Data source: French National Agency for Research on AIDS and Viral Hepatitis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bobo-Dioulasso, Burkina Faso